PURPOSE: Few recent U.S. studies have examined population-based patterns in prescription drug use and even fewer have considered detailed patterns by race/ethnicity. In a representative community sample, our objectives were to determine the most commonly used prescription drug classes, and to describe their use by age, gender, and race/ethnicity. METHODS: Cross-sectional epidemiologic study of 5503 (1767 black, 1877 Hispanic, 1859 white) community-dwelling participants aged 30-79 in the Boston Area Community Health (BACH) Survey (2002-2005). Using medication information collected from an in-home interview and medication inventory, the prevalence of use of a therapeutic class (95% confidence interval (95%CI)) in the past month was estimated by gender, age group, and race/ethnicity. Estimates were weighted inversely to the probability of sampling for generalizablity to Boston, MA. RESULTS: The therapeutic class containing selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants was most commonly used (14.6%), followed by statins (13.9%), beta-adrenergic blockers (10.6%), and angiotensin-converting enzyme (ACE) inhibitors (10.5%). Within all age groups and both genders, black participants were substantially less likely than white to use SSRI/SNRI antidepressants (e.g., black men: 6.0% [95%CI: 3.9-8.1%]; white men: 15.0% [95%CI: 10.2-19.4%]). Other race/ethnic differences were observed: for example, black women were significantly less likely than other groups to use benzodiazepines (e.g., black: 2.6% [95%CI: 1.2-3.9%]; Hispanic: 9.4% [95%CI: 5.8-13.0%]). CONCLUSIONS: Race/ethnic differences in use of prescription therapeutic classes were observed in our community sample. Examining therapeutic classes rather than individual drugs resulted in a different distribution of common exposures compared to other surveys.
PURPOSE: Few recent U.S. studies have examined population-based patterns in prescription drug use and even fewer have considered detailed patterns by race/ethnicity. In a representative community sample, our objectives were to determine the most commonly used prescription drug classes, and to describe their use by age, gender, and race/ethnicity. METHODS: Cross-sectional epidemiologic study of 5503 (1767 black, 1877 Hispanic, 1859 white) community-dwelling participants aged 30-79 in the Boston Area Community Health (BACH) Survey (2002-2005). Using medication information collected from an in-home interview and medication inventory, the prevalence of use of a therapeutic class (95% confidence interval (95%CI)) in the past month was estimated by gender, age group, and race/ethnicity. Estimates were weighted inversely to the probability of sampling for generalizablity to Boston, MA. RESULTS: The therapeutic class containing selective serotonin reuptake inhibitor/serotoninnorepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants was most commonly used (14.6%), followed by statins (13.9%), beta-adrenergic blockers (10.6%), and angiotensin-converting enzyme (ACE) inhibitors (10.5%). Within all age groups and both genders, black participants were substantially less likely than white to use SSRI/SNRI antidepressants (e.g., black men: 6.0% [95%CI: 3.9-8.1%]; white men: 15.0% [95%CI: 10.2-19.4%]). Other race/ethnic differences were observed: for example, black women were significantly less likely than other groups to use benzodiazepines (e.g., black: 2.6% [95%CI: 1.2-3.9%]; Hispanic: 9.4% [95%CI: 5.8-13.0%]). CONCLUSIONS: Race/ethnic differences in use of prescription therapeutic classes were observed in our community sample. Examining therapeutic classes rather than individual drugs resulted in a different distribution of common exposures compared to other surveys.
Authors: Ryne Paulose-Ram; Marc A Safran; Bruce S Jonas; Qiuping Gu; Denise Orwig Journal: Pharmacoepidemiol Drug Saf Date: 2007-05 Impact factor: 2.890
Authors: Lisa A Cooper; Junius J Gonzales; Joseph J Gallo; Kathryn M Rost; Lisa S Meredith; Lisa V Rubenstein; Nae-Yuh Wang; Daniel E Ford Journal: Med Care Date: 2003-04 Impact factor: 2.983
Authors: Jane L Givens; Thomas K Houston; Benjamin W Van Voorhees; Daniel E Ford; Lisa A Cooper Journal: Gen Hosp Psychiatry Date: 2007 May-Jun Impact factor: 3.238
Authors: Dima M Qato; G Caleb Alexander; Rena M Conti; Michael Johnson; Phil Schumm; Stacy Tessler Lindau Journal: JAMA Date: 2008-12-24 Impact factor: 56.272
Authors: Susan A Hall; Gretchen R Chiu; David W Kaufman; Gary A Wittert; Carol L Link; John B McKinlay Journal: BJU Int Date: 2011-09-27 Impact factor: 5.588
Authors: Susan A Hall; May Yang; Margaret A Gates; William D Steers; Sharon L Tennstedt; John B McKinlay Journal: J Urol Date: 2012-05-15 Impact factor: 7.450
Authors: James B Wetmore; Jonathan D Mahnken; Sally K Rigler; Edward F Ellerbeck; Purna Mukhopadhyay; Qingjiang Hou; Theresa I Shireman Journal: Am J Hypertens Date: 2012-12-28 Impact factor: 2.689
Authors: Abimereki D Muzaale; Matthew Daubresse; Sunjae Bae; Nadia M Chu; Krista L Lentine; Dorry L Segev; Mara McAdams-DeMarco Journal: Clin J Am Soc Nephrol Date: 2020-05-26 Impact factor: 8.237
Authors: Yassaman Vafai; Edwina H Yeung; Rajeshwari Sundaram; Melissa M Smarr; Nicole Gerlanc; William A Grobman; Daniel Skupski; Edward K Chien; Stefanie N Hinkle; Roger B Newman; Deborah A Wing; Angela C Ranzini; Anthony Sciscione; Jagteshwar Grewal; Cuilin Zhang; Katherine L Grantz Journal: Am J Perinatol Date: 2020-10-08 Impact factor: 3.079
Authors: Melissa M Smarr; Joe Bible; Nicole Gerlanc; Germaine M Buck Louis; Alaina Bever; Katherine L Grantz Journal: Pediatr Res Date: 2019-03-25 Impact factor: 3.756